The Walgreens Boots Alliance (NASDAQ:WBA – Get Rating) updated its earnings guidance for fiscal year 2023 on Thursday. The company provided EPS guidance for the period from $4.45 to $4.65, compared to a consensus EPS estimate of $4.48. The company issued revenue guidance of $137.5 billion from $133.5 billion, compared with a consensus revenue estimate of $134.8 billion.
Walgreens Boots Alliance deal up 0.8%
NASDAQ:WBA shares opened Thursday at $37.49. The company has a 50-day moving average price of $39.27 and a 200-day moving average price of $37.56. The stock has a market cap of $32.33 billion, a price/earnings ratio of 7.50, a PEG ratio of 2.73, and a beta of 0.75. The company has an equity ratio of 0.36, a quick ratio of 0.38 and a current ratio of 0.75. His one-year low in the Walgreens Boots Alliance is $30.39 and his one-year high is $55.00.
The Walgreens Boots Alliance (NASDAQ:WBA – Get Rating) announced its final results on Thursday, October 13th. The pharmacy operator reported earnings of $0.80 per share for the quarter, beating analysts’ consensus forecast of $0.78 by $0.02. The company’s revenue for the quarter was $32.45 billion, compared to consensus expectations of $32.17 billion. Walgreens Boots Alliance had a return on equity of 14.39% and a net profit margin of 3.27%. The company’s quarterly revenue fell 5.3% year-on-year. In the same quarter last year, the company earned him $1.17 EPS. On average, research analysts expect his Walgreens Boots Alliance EPS to be 4.51 this year.
Walgreens Boots Alliance Announces Dividend
The business recently announced a quarterly dividend, which was paid on Monday, December 12th. A dividend of $0.48 per share was issued to investors of record on Tuesday, November 15th. This represents his $1.92 dividend and his 5.12% dividend yield on an annualized basis. The ex-dividend date for this dividend was Monday, November 14. The Walgreens Boots Alliance payout ratio is currently 38.40%.
Analyst sets new price target
Several research firms have recently commented on the WBA. Truist Financial raised its price target for the Walgreens Boots Alliance to $44.00 from his $38.00 in a report on Tuesday, Nov. 8. StockNews.com downgraded Walgreens Boots Alliance shares from buy to hold in a report on Wednesday, Oct. 5. Cowen said in a research note on Tuesday, Nov. 22, that Walgreens Boots raised his Alliance stock from the market’s performance rating to an outperform rating and raised the company’s price target from his $43.00 to his $54.00. I pulled it up. UBS Group raised its price target on Walgreens Boots Alliance shares to his $40.00 in a research note on Monday, Nov. 28. Finally, Royal Bank of Canada lowered its price target for Walgreens Boots Alliance from $42.00 to $36.00 in a research note on Wednesday, Oct. 19, setting his performance rating for the company’s sector. One research analyst gave a sell rating, nine assigned a hold rating, and four assigned a buy rating to the company’s stock. Data from MarketBeat.com shows that the Walgreens Boots Alliance’s current consensus rating is Hold, with a consensus price target of $43.85.
insider trading
In related news, Director Nancy M. Schlichting sold 16,570 shares of the business in a transaction on Thursday, November 17th. The shares sold for an average of $39.89, and the total trading value he had was $660,977.30. After the transaction, the directors now own 5,515 shares of the company stock valued at $219,993.35. The sale is disclosed in legal documents to the Securities and Exchange Commission, available at this hyperlink. In other news for his Walgreens Boots Alliance, EVP Kevin M. Ban sold 10,303 shares in the company in his Friday, Nov. 18 deal. The shares sold at an average price of $40.19, giving him a total of $414,077.57. After the sale, Executive His Vice President now owns 27,916 shares of the company’s stock, valued at approximately $1,121,944.04. The sale was disclosed in legal documents to the Securities and Exchange Commission. This link is available here. In addition, Director Nancy M. Schlichting sold 16,570 shares of the business in a transaction on Thursday, November 17th. The shares sold for an average of $39.89, and the total trading value he had was $660,977.30. Following the closing of the sale, the directors now own 5,515 shares in the company, valued at approximately $219,993.35. Please see here for the disclosure of this sale. His 17.50% of shares are now owned by insiders.
Institutional investors consider Walgreens Boots Alliance
Institutional investors and hedge funds have recently changed positions in the company. Renaissance Technologies LLC increased his position in the Walgreens Boots Alliance by 179.9% in the first quarter. Renaissance Technologies LLC now owns 1,910,000 shares of the pharmacy operator worth $85,511,000 after purchasing an additional 1,227,700 of his shares last quarter. Cowa LLC increased its position in the Walgreens Boots Alliance by 10,678.3% in the first quarter. Cowa LLC now owns 695,954 shares of pharmacy operator stock valued at $312,000 after purchasing an additional 689,497 shares in the previous quarter. Cibc World Markets Corp won a new position in the Walgreens Boots Alliance in the first quarter worth approximately $21,167,000. Charles Schwab Investment Management Inc. increased his position in the Walgreens Boots Alliance by 7.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 5,132,750 shares of pharmacy operators worth $229,794,000 after purchasing an additional 358,403 shares in the previous quarter. Finally, Edgar Lomax Co. VA increased its position in the Walgreens Boots Alliance by 26.2% in the first quarter. Edgar Lomax Co. VA owns 1,591,390 shares of pharmacy operators worth $71,247,000 after purchasing an additional 330,080 shares in the previous quarter. Institutional investors and hedge funds own 56.71% of the company’s shares.
About Walgreens Boots Alliance
(get rating)
Walgreens Boots Alliance, Inc operates as an integrated healthcare, pharmacy and retailer in the United States (US), United Kingdom, Germany and internationally. It operates through his three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The US Retail Pharmacy segment sells prescription drugs and a range of retail products, including health, wellness, beauty, personal care, supplies and general merchandise, through retail drugstores.
read more
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to contact@marketbeat.com.
Listen to this before considering the Walgreens Boots Alliance.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Walgreens Boots Alliance is not on the list. did.
The Walgreens Boots Alliance is currently rated “Hold” among analysts, but the top rated analysts believe these five stocks are better buys.
See 5 stocks here
